Dermata Therapeutics annual return on equity
2021
2022
2023
2024
2025
Dermata Therapeutics Return on Equity (ROE) Growth & History (DRMA)
Dermata Therapeutics's return on equity was −194.20% for fiscal 2025.
View full Dermata Therapeutics company overviewDermata Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −194.20% | +116.25 pp |
| 2024 | 2024-12-31 | −310.44% | −184.49 pp |
| 2023 | 2023-12-31 | −125.96% | −6.78 pp |
| 2022 | 2022-12-31 | −119.18% | +108.92 pp |
| 2021 | 2021-12-31 | −228.09% | — |
Dermata Therapeutics quarterly return on equity
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −59.94% | −33.59 pp |
| Q1 2026 | 2026-03-31 | −29.24% | +22.74 pp |
| Q4 2025 | 2025-12-31 | −36.57% | +63.43 pp |
| Q3 2025 | 2025-09-30 | −35.34% | +43.40 pp |
| Q2 2025 | 2025-06-30 | −26.34% | +53.06 pp |
| Q1 2025 | 2025-03-31 | −51.99% | +9.69 pp |
| Q4 2024 | 2024-12-31 | −99.99% | −66.55 pp |
| Q3 2024 | 2024-09-30 | −78.74% | −54.93 pp |
| Q2 2024 | 2024-06-30 | −79.40% | −58.29 pp |
| Q1 2024 | 2024-03-31 | −61.68% | −29.93 pp |
| Q4 2023 | 2023-12-31 | −33.44% | −8.69 pp |
| Q3 2023 | 2023-09-30 | −23.82% | +4.49 pp |
| Q2 2023 | 2023-06-30 | −21.11% | +10.07 pp |
| Q1 2023 | 2023-03-31 | −31.75% | −0.73 pp |
| Q4 2022 | 2022-12-31 | −24.75% | −2.15 pp |
| Q3 2022 | 2022-09-30 | −28.31% | +0.28 pp |
| Q2 2022 | 2022-06-30 | −31.18% | — |
| Q1 2022 | 2022-03-31 | −31.03% | — |
| Q4 2021 | 2021-12-31 | −22.59% | — |
| Q3 2021 | 2021-09-30 | −28.58% | — |
Dermata Therapeutics return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Dermata Therapeutics's return on equity increased from −228.09% to −194.20%, a change of +33.90 percentage points. The latest reported quarter, Q2 2026, shows −59.94%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Dermata Therapeutics source filings ↗